GlassScriptPhysician profile
Zachary Lagrue
NPI 1972269629
$2,637.15
in general payments reported to CMS, 2019-2025
23 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $276 · 2023: $865 · 2024: $485 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.06 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $807.61 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $366.79 | 2022-2025 | Repatha, Repatha, Otezla |
| Boston Scientific Corporation | $221.87 | 2024-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.01 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $139.72 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.77 | 2023-2024 | Lifevest |
| Pfizer INC. | $124.66 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $124.17 | 2023-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $84.33 | 2023 | Mounjaro |
| Inspire Medical Systems, INC. | $73.65 | 2023 | Inspire |
| Scpharmaceuticals INC. | $70.35 | 2025 | |
| Novartis Pharmaceuticals Corporation | $64.25 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $49.79 | 2023-2025 | Verquvo, Capvaxive |
| Abbvie INC. | $48.83 | 2023 | |
| Shield Therapeutics INC | $24.33 | 2023 | Accrufer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.59 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.62 | 2024 | Uptravi, Opsumit |
| Biohaven Pharmaceutical Holding Company LTD. | $18.88 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.83 | 2023 | Belbuca |
| Esperion Therapeutics, INC. | $15.56 | 2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.32 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.62 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Lagrue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.